163 related articles for article (PubMed ID: 1834159)
1. The role of interferons in the management of carcinoid tumours.
Oberg K; Eriksson B
Br J Haematol; 1991 Oct; 79 Suppl 1():74-7. PubMed ID: 1834159
[TBL] [Abstract][Full Text] [Related]
2. The role of interferons in the management of carcinoid tumors.
Oberg K; Eriksson B
Acta Oncol; 1991; 30(4):519-22. PubMed ID: 1854509
[TBL] [Abstract][Full Text] [Related]
3. Octreotide and interferon alfa: a new combination for the treatment of malignant carcinoid tumours.
Tiensuu Janson EM; Ahlström H; Andersson T; Oberg KE
Eur J Cancer; 1992; 28A(10):1647-50. PubMed ID: 1382492
[TBL] [Abstract][Full Text] [Related]
4. Interferons in the management of neuroendocrine tumors and their possible mechanism of action.
Oberg K
Yale J Biol Med; 1992; 65(5):519-29; discussion 531-6. PubMed ID: 1340065
[TBL] [Abstract][Full Text] [Related]
5. Treatment of advanced neuroendocrine tumours using combination chemotherapy with lomustine and 5-fluorouracil.
Kaltsas GA; Mukherjee JJ; Isidori A; Kola B; Plowman PN; Monson JP; Grossman AB; Besser GM
Clin Endocrinol (Oxf); 2002 Aug; 57(2):169-83. PubMed ID: 12153595
[TBL] [Abstract][Full Text] [Related]
6. Treatment of malignant carcinoid tumors: a randomized controlled study of streptozocin plus 5-FU and human leukocyte interferon.
Oberg K; Norheim I; Alm G
Eur J Cancer Clin Oncol; 1989 Oct; 25(10):1475-9. PubMed ID: 2480243
[TBL] [Abstract][Full Text] [Related]
7. Recombinant alpha-2b interferon in patients with malignant carcinoid tumour.
Basser RL; Lieschke GJ; Sheridan WP; Fox RM; Green MD
Aust N Z J Med; 1991 Dec; 21(6):875-8. PubMed ID: 1726359
[TBL] [Abstract][Full Text] [Related]
8. Combined alpha- and gamma-interferon therapy for malignant midgut carcinoid tumors. A phase I-II trial.
Janson ET; Kauppinen HL; Oberg K
Acta Oncol; 1993; 32(2):231-3. PubMed ID: 8323762
[TBL] [Abstract][Full Text] [Related]
9. Interferons alone or in combination with chemotherapy or other biologicals in the treatment of neuroendocrine gut and pancreatic tumors.
Oberg K; Eriksson B; Janson ET
Digestion; 1994; 55 Suppl 3():64-9. PubMed ID: 7698540
[TBL] [Abstract][Full Text] [Related]
10. A pilot study of combination therapy with interferon-alpha-2a and 5-fluorouracil in metastatic carcinoid and malignant endocrine pancreatic tumours.
Hughes MJ; Kerr DJ; Cassidy J; Soukop M; McGregor K; Blackburn N; Yosef H; Kaye SB
Ann Oncol; 1996 Feb; 7(2):208-10. PubMed ID: 8777180
[TBL] [Abstract][Full Text] [Related]
11. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon.
Janson ET; Oberg K
Acta Oncol; 1993; 32(2):225-9. PubMed ID: 7686765
[TBL] [Abstract][Full Text] [Related]
12. [Therapy of metastatic carcinoid with the somatostatin analog octreotide and with recombinant interferon alfa 2b].
Linkesch M; Kuzmits R; Geyer G
Wien Klin Wochenschr; 1989 Jun; 101(13):455-7. PubMed ID: 2763566
[TBL] [Abstract][Full Text] [Related]
13. Treatment with alpha-interferon versus alpha-interferon in combination with streptozocin and doxorubicin in patients with malignant carcinoid tumors: a randomized trial.
Janson ET; Rönnblom L; Ahlström H; Grandér D; Alm G; Einhorn S; Oberg K
Ann Oncol; 1992 Sep; 3(8):635-8. PubMed ID: 1450046
[TBL] [Abstract][Full Text] [Related]
14. Medical treatment of neuroendocrine gut and pancreatic tumors.
Oberg K; Eriksson B
Acta Oncol; 1989; 28(3):425-31. PubMed ID: 2472826
[TBL] [Abstract][Full Text] [Related]
15. Malignant rectal carcinoid: a sequential multidisciplinary approach for successful treatment of hepatic metastases.
Azizkhan RG; Tegtmeyer CJ; Wanebo HJ
Am J Surg; 1985 Feb; 149(2):210-4. PubMed ID: 3970317
[TBL] [Abstract][Full Text] [Related]
16. [Carcinoid tumor with revealed by skin manifestation].
Reichert S; Truchetet F; Cuny JF; Grandidier M
Ann Dermatol Venereol; 1994; 121(6-7):485-8. PubMed ID: 7535513
[TBL] [Abstract][Full Text] [Related]
17. Interferon-alpha 2b, with or without prior hepatic artery embolization: clinical response and survival in mid-gut carcinoid patients. The Norwegian carcinoid study.
Jacobsen MB; Hanssen LE; Kolmannskog F; Schrumpf E; Vatn MH; Bergan A
Scand J Gastroenterol; 1995 Aug; 30(8):789-96. PubMed ID: 7481548
[TBL] [Abstract][Full Text] [Related]
18. Liver metastases of digestive endocrine tumours: natural history and response to medical treatment.
Skinazi F; Zins M; Menu Y; Bernades P; Ruszniewski P
Eur J Gastroenterol Hepatol; 1996 Jul; 8(7):673-8. PubMed ID: 8853257
[TBL] [Abstract][Full Text] [Related]
19. Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: development of neutralizing interferon antibodies and possible loss of antitumor activity.
Oberg K; Alm G; Magnusson A; Lundqvist G; Theodorsson E; Wide L; Wilander E
J Natl Cancer Inst; 1989 Apr; 81(7):531-5. PubMed ID: 2466128
[TBL] [Abstract][Full Text] [Related]
20. Gastrointestinal carcinoid tumours. Histogenetic, histochemical, immunohistochemical, clinical and therapeutic aspects.
Wilander E; Lundqvist M; Oberg K
Prog Histochem Cytochem; 1989; 19(2):1-88. PubMed ID: 2662260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
